ESRG and colon adenocarcinoma: In conclusion, our comprehensive pan-cancer analysis of ESRG across various cancer types demonstrated its potential to be used as a diagnostic biomarker in COAD, LUSC, READ, and UCEC and a promising prognostic biomarker in LGG. Furthermore, our findings figured out relatively significant variations in ESRG expression between normal and different cancer stages in COAD, LUSC, and READ.